NaVette Bio builds easy-to-use, modular delivery tools – designed for drug developers, scientists, and engineers working on the next generation of therapies.
Interested in learning more?
Meet the co-founders driving innovation at Navette Bio.
Chief Executive Officer
Julie is a biotech founder and bioengineer with a track record of advancing cell therapies from concept to clinic. At Juno Therapeutics, Bristol Myers Squibb, and Sana Biotechnology, she built and led technology and process development teams focused on non-viral delivery and scalable manufacturing. At Navette Bio, she brings this experience to developing practical, reagent-based delivery tools that fit seamlessly into real-world cell therapy workflows. Julie earned her Ph.D. in Bioengineering from the University of Washington and her B.S. in Chemical Engineering from MIT.
Chief Scientific Officer
Miriam is a translational immunologist with a background in driving therapeutic programs through discovery, biomarker development, and clinical strategy. At Bristol Myers Squibb and the Allen Institute for Immunology, she led cross-functional teams working at the interface of data science and immunology to inform clinical development. At Navette Bio, she applies this expertise to designing delivery solutions that are both scientifically rigorous and clinically actionable. Miriam holds a Ph.D. in Bioengineering from Stanford University.
We’d love to hear from you! Reach out to learn more about our technology or to collaborate with us, send us an email at info@navette.bio.